The global anti-idiopathic pulmonary fibrosis drugs market is expected to grow at a CAGR of 16.7% in the first half of the forecast period. In 2016, the anti-fibrotics held the largest market share (52%) followed by the tyrosine kinase inhibitors.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 162-page report you will receive 57 tables and 97 figures– all unavailable elsewhere.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Anti-Idiopathic Pulmonary Fibrosis Drugs market forecasts to 2027
• This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by mechanism of action: – Antifibrotics – Tyrosine Kinase Inhibitors – Anti-inflammatory Drugs – Immunosuppressants – Other MoA
• This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by Innovator and Off-label drugs: – Innovator Drugs – Off-label Drugs
• This report provides individual revenue forecasts to 2027 for these regional and national markets: – US – Japan – EU5: Germany, France, the UK, Italy, Spain – Rest of Europe – Rest of World
• This report provides individual revenue forecasts to 2027 for these marketed drugs: – Esbriet – Ofev
• Our study gives qualitative analysis of the anti-idiopathic pulmonary fibrosis drugs market. It discusses: – Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the G7 markets (Historical 2010-2015, 2016 data, Forecast 2017-2027) – Epidemiology of Idiopathic Pulmonary Fibrosis by disease severity – Epidemiology of Idiopathic Pulmonary Fibrosis by gender – Discussion on novel clinical molecules under development for the treatment of Idiopathic Pulmonary Fibrosis – Pricing and Reimbursement Overview on Ofev and Esbriet (by NICE, SMC, PBAC, CADTH, G-BA, HAS) – A SWOT Analysis on the anti-idiopathic pulmonary fibrosis drugs market
Visiongain’s study is intended for anyone requiring commercial analyses for the global Anti-Idiopathic Pulmonary Fibrosis Drugs Market. You find data, trends and predictions.
Buy our report today Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2027: Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs, Off-label Drugs.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview
1.1 Why You Should Read This Report
1.2 How This Report Delivers
1.3 Key Questions Answered by This Analytical Report Include:
1.4 Who is This Report For?
1.5 Methodology
1.5.1 Primary Research
1.5.2 Secondary Research
1.5.3 Market Evaluation & Forecasting Methodology
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Visiongain Reports
1.8 About Visiongain
2. Introduction to the Idiopathic Pulmonary Fibrosis (IPF)
2.1 What is IPF?
2.2 Aetiology – Causes and Risk Factors
2.3 Symptoms
2.4 Stages of IPF
2.5 Diagnosis
2.5.1 Diagnostic Tests
2.5.2 Pulmonary Function Testing/Lung Function Testing
2.5.3 Oximetry
2.5.4 Lung Biopsy
2.5.5 Chest X-ray
2.5.6 Computerized Tomography (CT)
2.5.7 Echocardiogram
2.6 Epidemiology
2.6.1 Methodology
2.6.2 Epidemiology by Country
2.6.3 Epidemiology by Disease Severity
2.6.4 Epidemiology by Gender
2.6.5 Historical Prevalence in Major Markets
2.6.6 Forecast of IPF in Major Markets: 2016-2027
2.6.6.1 The US
2.6.6.2 France
2.6.6.3 Germany
2.6.6.4 The United Kingdom
2.6.6.5 Italy
2.6.6.6 Spain
2.6.6.7 Japan
2.7 Humanistic and Economic Burden
2.7.1 Co-morbidities
2.7.2 Mortality
2.7.3 Healthcare Utilization & Economic Burden
2.8 Prevention and Treatment
2.8.1 Guidelines
2.8.2 Non-pharmacologic Management
2.8.2.1 Quit Smoking
2.8.2.2 Oxygen therapy
2.8.2.3 Pulmonary Rehabilitation
2.8.2.4 Vaccination
2.8.2.5 Maintain Healthy Weight
2.8.2.6 Lung Transplantation
2.8.3 Pharmacologic Treatments
3. Introduction to the Global Anti- Anti-Idiopathic Pulmonary Fibrosis Drugs Market
3.1 Market Structure
3.2 Market Definition and Scope
3.3 Classification by Mechanism of Action
3.3.1 Anti-fibrotics
3.3.2 Tyrosine Kinase Inhibitors
3.3.3 Anti-inflammatory Drugs
3.3.4 Immunosuppressants
3.3.5 Other Mechanisms
3.4 Classification by Innovator or Off-label Drugs
3.4.1 Innovator Drugs
3.4.2 Off-label Drugs
4. Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market 2017-2027
4.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market 2016
4.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast 2017-2027
4.3 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action
4.4 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Mechanism of Action: Forecast 2017-2027
4.4.1 Global Anti-fibrotics Drugs Market Forecast, 2016-2027
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
The global Single-Use Bioprocessing Probes & Sensors market was valued US$2,493.8 million in 2022 and is projected to grow at a CAGR of 15.2% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
